Skip to content
RelibillMedical Billing
RelibillMedical Billing

Specialty

Rheumatology billing is a visit plus a drug pathway that can dwarf the visit.

Rheumatology practices bill complex E/M and a large volume of injectable or infused drugs. The drug pathway is an authorization, a dose, a waste record, and an administration code. Joint injections billed the same day as a visit need a distinct evaluation or they fold into the procedure.

Specialty rules are applied to the practice's payers, documentation, and schedule during the engagement.

Where the billing gets difficult

Biologic authorizations that expire mid-plan

A standing order is not a standing authorization. Infusions given after the auth expires deny at a high dollar amount.

Wastage documented after the fact

Single-dose vial wastage has documentation and modifier rules. Reconstructing it later is weak.

Injection visits coded as high E/M by default

A planned injection with a brief check is not automatically a separate high-level visit.

Coding considerations

Drug and administration

The product, the units, and the administration or infusion time are coded from the medication record.

Wastage modifiers

Modifiers used to report discarded amounts are applied only when the drug and the payer rule call for them and the record shows the discard.

Joint injection and E/M

A separate visit needs a significant, separately identifiable evaluation. The injection note alone is the procedure.

Documentation the claim needs

  • Authorization span and dose
  • Start and stop times for infusions
  • Amount used and amount discarded, when wastage is billed
  • A distinct assessment when an E/M is billed with an injection

Reimbursement complexity

A single denied biologic can matter more than a week of office visits. The control is authorization and dose match, not a faster appeal letter. Buy-and-bill versus specialty pharmacy changes whether the practice bills the drug at all. That path is confirmed per payer before a drug code is added. Patient cost sharing on these drugs is high enough that an estimate conversation belongs at scheduling, labeled as an estimate.

Proposed approach

  1. 01

    Know who buys the drug

    Buy-and-bill and specialty pharmacy are flagged per payer so the practice does not bill a drug it did not purchase.

  2. 02

    Check auth before the chair

    Infusions without a current authorization are an exception, not a routine.

  3. 03

    Code injections from the procedure

    E/M is added only when the note supports a separate evaluation.

Workflow checks

  • Auth span check
  • Buy-and-bill versus pharmacy flag
  • Infusion time capture
  • Injection versus E/M review

Questions

Do you purchase the drugs?

No. Buy-and-bill is the practice's purchasing decision. Billing support codes what the practice administered and is allowed to bill.

Will you appeal every biologic denial?

We appeal when the record and the deadline support it. A denial for an expired authorization is often a corrected process, not a medical-necessity argument.

Related services

Talk through rheumatology billing.

Bring the queues you can already name. Leave patient identifiers off the form.

Contact the office